Ticagrelor - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The ticagrelor market size is projected to be USD 1.86 billion in 2025, USD 1.99 billion in 2026, and reach USD 2.80 billion by 2031, growing at a CAGR of 7.04% from 2026 to 2031. This report is Segmented by Dosage Strength (60 Mg Tablets, 90 Mg Tablets), by Indication (Acute Coronary Syndrome, Ischemic Stroke), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Institutional and Tender Supply), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Forecasts are in Value (USD).

Global Ticagrelor Market Trends and Insights

Persistent Cardiovascular Event Burden Sustains Baseline Demand

Ischemic heart disease remained the leading cause of cardiovascular mortality in 2023. This disease burden gives the ticagrelor market a stable clinical base because acute coronary events require prompt antiplatelet treatment. Better access to reperfusion care can increase the population that survives an event and needs secondary prevention afterward. Global cardiovascular deaths are projected to rise from 20.5 million in 2025, even as age-standardized mortality rates decline, which points to continued growth in absolute treatment need. The ticagrelor market, therefore, depends on both initial hospital treatment and continuing care after an event. This pattern makes demand less dependent on a single acute dispensing episode.

Guideline-Led Preference Embeds Ticagrelor in Standard ACS Protocols

The 2025 ACC, AHA, ACEP, NAEMSP, and SCAI guideline recommends ticagrelor or prasugrel over clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. That recommendation supports ticagrelor use in hospital pathways where treatment choices are often set through clinical protocols. The same guideline supports a switch to ticagrelor monotherapy 1 month or later after percutaneous coronary intervention in suitable patients to lower bleeding risk while preserving ischemic protection. This approach can extend treatment beyond the earliest stage of dual antiplatelet therapy. European clinical guidance also discusses personalized antithrombotic treatment and ticagrelor-based de-escalation for selected patients. The shared direction of North American and European guidance helps maintain a clinical role for ticagrelor even when lower-priced products enter formularies.

Bleeding, Dyspnea, and Treatment Complexity Limit Persistence

Bleeding and dyspnea can limit patient selection and continuation in the ticagrelor market. A 2024 study found dyspnea during the first month of ticagrelor-based dual antiplatelet therapy in 20.6% of patients. Adherence was lower among patients who continued ticagrelor than among those de-escalated to clopidogrel, especially for patients with dyspnea, at 81.1% and 91.5%, respectively. A 2024 network meta-analysis also reported the highest risk of premature discontinuation for ticagrelor among the major P2Y12 inhibitors. These issues narrow the eligible patient group and make counseling, follow-up, and individualized risk assessment necessary. Aspirin dose considerations and drug interactions add further complexity when clinicians choose and monitor therapy.

Other drivers and restraints analyzed in the detailed report include:

• Generic Access and Hospital Procurement Modernization Broaden Availability
• Stroke, TIA, and Extended Post-MI Protocols Expand Treatment Pathways
• Generic Price Erosion and Uneven Follow-Up Capacity Constrain Value

Segment Analysis

The 90 mg formulation accounted for 63.18% of the segment value in 2025. Its position reflects its central use in acute and post-acute coronary syndrome treatment and in the stroke and transient ischemic attack setting. A loading dose followed by 90 mg twice daily during the first year after an acute coronary syndrome event supports regular hospital and outpatient replenishment. The formulation remains relevant where clinicians use guideline-based acute coronary care pathways. Price pressure is therefore more likely to change supplier choice than the clinical need for treatment.

The 60 mg formulation is forecast to grow at an 8.5% CAGR from 2026 to 2031, the highest rate within dosage strength. Extended dual antiplatelet therapy with ticagrelor 60 mg twice daily reduced cardiovascular death, myocardial infarction, or stroke in eligible patients with prior myocardial infarction in the PEGASUS evidence base. European guidance favors the 60 mg dose for extended therapy after 12 months in suitable patients with prior myocardial infarction, while real-world persistence can still be affected by adverse effects and patient-led discontinuation. Electronic health record screening and pharmacist reviews can help identify patients who meet treatment criteria. Demand for 60 mg tablets, therefore, depends on consistent patient identification and support after the initial acute treatment period.

Complete Report Scope:

• By Dosage Strength
  • 60 mg Tablets
  • 90 mg Tablets
• By Indication
  • Acute Coronary Syndrome
  • Ischemic Stroke
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Institutional and Tender Supply
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 43.18% of the ticagrelor market share in 2025. High percutaneous coronary intervention volumes, clinical guideline use, and historically higher branded prices supported its leading position. Generic competition has lowered the price per unit while preserving access to treatment, and the 2025 acute coronary syndrome guideline continues to support ticagrelor use in appropriate patients undergoing percutaneous coronary intervention. Canada has entered a more active generic substitution phase following patent expiry. Mexico adds demand through expanded healthcare infrastructure and treatment of acute coronary syndrome in urban hospitals.

Europe is the second-largest contributor to ticagrelor revenues, and generic competition emerged in several countries before the U.S. shift. AstraZeneca reported that generic erosion in Europe contributed to the Brilinta decline reported for fiscal year 2024. Germany, the United Kingdom, and France remain major markets by volume, while Spain and Italy retain meaningful hospital use. European treatment guidance supports personalized antithrombotic approaches, including ticagrelor-based strategies for selected patients. South America grows through private hospital networks and public procurement, with Brazil and Argentina leading the region.

Asia-Pacific is forecast to grow at an 8.8% CAGR from 2026 to 2031, the fastest rate among regions. Rising cardiovascular incidence, hospital procurement modernization, and generic affordability support the ticagrelor market in this region. India recorded a 50% increase in cardiac drug sales between June 2021 and June 2025, indicating stronger institutional demand for cardiovascular medicines. China uses centralized procurement that can lower branded prices and favor suppliers that can fulfill large hospital tenders.

List of Companies Covered in this Report:

• Alembic Pharmaceuticals
• Alkem Laboratories Limited
• Apotex
• Ascend Laboratories, LLC
• AstraZeneca
• Aurobindo Pharma
• Bionpharma Inc.
• Cipla
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Hetero Labs Limited
• Intas Pharmaceutical
• Lupin
• Novadoz Pharmaceuticals LLC
• ScieGen Pharmaceuticals, Inc.
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals Limited
• Viatris
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support